Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Department of Internal Medicine, Metro Health Medical Center, Cleveland, OH 44109, USA.
Medicina (Kaunas). 2024 Sep 9;60(9):1473. doi: 10.3390/medicina60091473.
: Proteomics encompasses the exploration of protein composition, regulation, function, and pathways. Its influence spans diverse clinical fields and holds promise in addressing various women's health conditions, including cancers, osteoporosis, and cardiovascular disorders. However, no comprehensive summary of proteomics and menopausal health exists. Our objective was to summarize proteomic profiles associated with diseases and disorders in peri- and postmenopausal women. : We conducted a comprehensive search of databases including PubMed, Google Scholar, the Cochrane database, Elsevier, and ScienceDirect until 2022. A total of 253 studies were identified, and 41 studies met the inclusion criteria to identify data of interest. These included the study design, disease, and proteomics/proteins of significance, as described by the authors. : The 41 studies covered diverse areas, including bone disorders (10 studies), cardiovascular diseases (5 studies), oncological malignancies (10 studies), and various conditions, such as obesity, nonalcoholic liver disease, the effects of hormone replacement therapy, and neurological diseases (16 studies). The results of our study indicate that proteomic profiles correlate with heart disease in peri- and postmenopausal women, with distinct sex differences. Furthermore, proteomic profiles significantly differ between women with and without osteoporosis. Additionally, patients with breast, ovarian, and endometrial cancer exhibit notable variations in proteomic profiles compared to those without these conditions. : Proteomics has the potential to enhance risk assessment and disease monitoring in peri- and postmenopausal women. By analyzing unique protein profiles, clinicians can identify individuals with heightened susceptibility to specific diseases or those already affected by established conditions. This review suggests that there is sufficient preliminary data related to proteomics in peri- and postmenopausal women for early identification of cardiovascular disease, osteoporosis, and cancers, disease monitoring, and tailoring individualized therapies. Rigorous validation studies involving large populations are essential before drawing definitive conclusions regarding the clinical applicability of proteomic findings.
蛋白质组学涵盖了蛋白质组成、调控、功能和途径的研究。它的影响跨越了多个临床领域，并在解决各种女性健康问题方面具有潜力，包括癌症、骨质疏松症和心血管疾病。然而，目前尚无关于蛋白质组学和绝经后健康的综合总结。我们的目标是总结与绝经前和绝经后妇女疾病和障碍相关的蛋白质组学特征。
我们全面检索了包括 PubMed、Google Scholar、Cochrane 数据库、Elsevier 和 ScienceDirect 在内的数据库，检索时间截至 2022 年。共确定了 253 项研究，其中 41 项研究符合纳入标准，以确定作者描述的有意义的疾病和蛋白质组学/蛋白质数据。
这 41 项研究涵盖了广泛的领域，包括骨骼疾病（10 项研究）、心血管疾病（5 项研究）、肿瘤恶性肿瘤（10 项研究）以及各种疾病，如肥胖、非酒精性肝病、激素替代治疗的影响和神经疾病（16 项研究）。我们的研究结果表明，蛋白质组学特征与绝经前和绝经后妇女的心脏病相关，且存在明显的性别差异。此外，骨质疏松症妇女和非骨质疏松症妇女的蛋白质组学特征存在显著差异。此外，与没有这些疾病的妇女相比，患有乳腺癌、卵巢癌和子宫内膜癌的妇女的蛋白质组学特征存在明显差异。
蛋白质组学有可能增强绝经前和绝经后妇女的风险评估和疾病监测。通过分析独特的蛋白质谱，临床医生可以识别出对特定疾病易感性较高或已经患有已确立疾病的个体。本综述表明，关于绝经前和绝经后妇女蛋白质组学的初步数据足够充分，可以早期识别心血管疾病、骨质疏松症和癌症、疾病监测以及定制个体化治疗。在得出关于蛋白质组学发现的临床适用性的明确结论之前，需要进行涉及大量人群的严格验证研究。
